OCA improves non-invasive markers of NASH, advanced fibrosis

Early and sustained improvements in non-invasive markers of nonalcoholic steatohepatitis and advanced fibrosis were observed in patients treated with obeticholic acid, according to research presented at The Digital International Liver Congress.“Improvements over time were generally consistent in patients with stage 2 or 3 fibrosis at baseline,” Jerome Boursier, MD, PhD, from Angers University Hospital in France, said during his presentation. “OCA treatment was associated with favorable shifts in [Fibroscan-AST] score.”Boursier and colleagues randomly assigned patientsRead More

Share on facebook
Share on twitter
Share on linkedin